CereXis is a clinical-stage biopharmaceutical company developing treatments for rare tumors. CereXis is the first company to be spun out of Recursion. Recursion is a digital biology company discovering life-changing medicines with a data-centric, target-agnostic approach.


Cerexis lead program, REC-2282 is in clinical development for the treatment of patients with Neurofibromatosis type 2 (NF2), an autosomal dominant syndrome characterized by multiple recurrent tumors of the nervous system that are associated with significant morbidities and mortality. NF2 is most commonly associated with bilateral vestibular schwannomas, also known as acoustic neuromas. These are benign (non-cancerous) tumors that occur on the nerves responsible for balance and hearing in the inner ear. Patients may also develop meningiomas, slow-growing tumors that usually emerge on the surface of the brain and in severe cases can be life threatening.


CereXis is headquartered in New York.

Meet The Team

Shafique Virani, MD FRCS

Chief Executive Officer

  • Chief Corporate Development Officer at Recursion, CereXis’ parent company, and head of Recursion’s clinical programs

  • Previously, Chief Executive Officer of Navire Pharma and CoA Therapeutics, which are two subsidiaries at BridgeBio Pharma

  • Served as Global Head of Neuroscience, Ophthalmology and Rare Disease Partnering at Roche/Genentech

  • Trained as a neurosurgeon in Cambridge, U.K. and Boston, and holds the Fellowship of the Royal College of Surgeons of England, in addition to a medical degree from the University of Nottingham

Ajay Aggarwal MD, MBA

Chief Medical Officer

  • Skilled clinician with a decade of global drug development experience in rare, pulmonary, genetic and immunological diseases

  • Advanced multiple products through various phases of clinical development, in large (AstraZeneca) and small pharmaceutical companies- most recently at Insmed

  • ABIM certifications in Internal Medicine and Pulmonary Medicine (Current), Critical Care and Sleep Medicine (Past); Fellow American College of Chest Physicians

  • Previously Chief of Medicine at VA Medical Center and Associate Professor at University of North Dakota, Fargo

  • Completed medical school from All India Institute of Medical Sciences; Pulmonary and Critical Care fellowship and Internal Medicine residency from SUNY Buffalo

  • MBA from Kellogg School of Management

Chris Gibson, PhD

Member, Board of Directors

  • ​Co-Founder and CEO of CereXis’ parent company, Recursion

  • Developed the core technology underlying Recursion 

  • Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia

  • Degrees in bioengineering and managerial studies from Rice University; PhD in Bioengineering from the University of Utah

Tina Larson

Member, Board of Directors

  • President and Chief Operating Officer of CereXis’ parent company, Recursion

  • More than 20 years’ experience in the biopharma industry, predominantly at Genentech

  • Most recently, Senior Vice President and Executive Committee member at Achaogen

  • Distinguished Alumna of Colorado State University’s College of Engineering where she serves on the Dean’s Advisory Board